Navigation Links
Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Date:8/19/2007

hich should not be given to healthy volunteers, this evaluation is being done in previously untreated elderly patients with de novo poor-risk AML who receive Cloretazine(R) (VNP40101M) therapy.

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. A Phase II trial of Cloretazine(R) (VNP40101M) in small cell lung cancer is also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. In preclinical studies, Vion is also evaluating VNP40541, a hypoxia-selective compound, and hydrazone compounds. The Company also is seeking development partners for TAPET(R), its modified Salmonella vector used to deliver anticancer agents directly to tumors. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies or clinical trials are not predictive of safety and efficacy results in later clinical trials, the need for additional research and testing, the potential inability to secure external sources of funding to continue operations, the inability to access capital and f
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 2015 Amgen (NASDAQ: AMGN ) ... 3, global, randomized, placebo-controlled trials evaluating AMG 416, ... hyperparathyroidism (SHPT) in patients with chronic kidney disease ... endpoint, demonstrating that a greater proportion of patients ... than 30 percent reduction in parathyroid hormone (PTH) ...
(Date:5/28/2015)... and HOUSTON , May 28, 2015 /PRNewswire/ ... today reported financial results for the second quarter and three ... otherwise, are expressed in Canadian dollars and in accordance with ... ESSA recorded a net loss of $5.9 ... March 31, 2015 (Q2-2015), compared to a net loss of ...
(Date:5/28/2015)... , May 28, 2015  IRIDEX Corporation (NASDAQ: IRIX ... Officer James H. Mackaness is scheduled to present ... at 9:00 am PT in Los Angeles ... may be accessed on the Event Calendar of the Investors ... of the webcast will be available shortly after the conclusion ...
Breaking Medicine Technology:Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 3Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 4Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 6Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 7Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 2Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 3Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 4Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 5
... Oct. 5 Osseon Therapeutics, Inc. announced its ... North American Spine Society,s (NASS) annual meeting in ... facilitate treatment of vertebral compression fractures (VCFs) that ... fibrotic metastases.  The Osseoflex DR Steerable Bone Drill ...
... SUNNYVALE, Calif., Oct. 5 Accuray Incorporated (Nasdaq: ... of radiosurgery, announced today that the company was awarded a ... U.S. Government to be used toward further development of a ... grant will fund the development of a next generation, compact ...
Cached Medicine Technology:Osseon® Therapeutics Introduces New Osseoflex® DR Steerable Bone Drill 2Accuray Awarded $1 Million Grant by U.S. Government 2Accuray Awarded $1 Million Grant by U.S. Government 3
(Date:5/29/2015)... May 29, 2015 Johnson & ... a confidential Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ) settlement ... due to his use of the antipsychotic medication. ... selected for the third bellwether trial to involve ... litigation underway in Pennsylvania’s Philadelphia Court of Common ...
(Date:5/29/2015)... Inspire Nexus, a new social network ... the question many life coaches have asked, "How do ... hours necessary to become a credentialed Coach?" , Many ... not for long. Inspire Nexus, a social network for ... Coaches who have experience coaching a certain number of ...
(Date:5/29/2015)... Chicago, Ill (PRWEB) May 29, 2015 ... Care , a dozen medical pioneers recognized by a ... changed the course of cancer treatment. Honorees will be ... of Cancer Care™ Award Ceremony, held 8:30-11:00 p.m. CDT ... , The 2015 honorees are being recognized for groundbreaking ...
(Date:5/29/2015)... 2015 The Global Allopurinol Industry ... on the current state of the Allopurinol industry.With ... statistics on the state of the industry and ... for companies and individuals interested in the market. ... industry including definitions, classifications, applications and industry chain ...
(Date:5/29/2015)... CA (PRWEB) May 29, 2015 ... their expertise to the Los Angeles County clinics ... diagnostic procedures are now being offered at all ... Orange County, and San Bernardino County. , ... motor neurons send electrical impulses throughout the ...
Breaking Medicine News(10 mins):Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 2Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 3Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 2Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 3Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 4Health News:Allopurinol Industry (Global, China) 2015 Research Analysis and 2020 Forecasts 2Health News:Healthpointe Is Now Offering EMG and NCV Diagnostics at All Clinics throughout Southern California. 2
... ... driving on icy highways. , ... New York, NY (PRWEB) January 26, 2010 -- When rain falls or water collects on ... says., , ,“Black ice is as dangerous as it is difficult to see,” said ...
... ... of its renovated website StandsandMounts.com. The company that has been selling TV stands and mounts ... the month of February to celebrate the grand opening of the new, user-friendly website. Everyday ... ...
... ... much easier, safe and energy saving. , ... (PRWEB) January 26, 2010 -- Over past several years in struggling and integrating ... lift , which is made by Apexcare, will be completed during this coming March in ...
... Preoperative computed tomography (CT) may help reduce unnecessary ... appendicitis, according to a new study appearing in the ... "We found that rising utilization of preoperative CT over ... coincided with a significant decrease in negative appendectomies among ...
... , , WASHINGTON , Jan. 25 ... guilty today for her role in a Detroit -area home ... of the Criminal Division; U.S. Attorney for the Eastern District ... Arena of the FBI,s Detroit Field Office; and Special Agent in ...
... Harpers Ferry completely right, completely wrong, or a mix of both? Was ... WICHITA, Kan. , Jan. 25 The following was released ... Statement of Randall Terry : , "We are not coming to ... rest with the jury. However, there are those who want to pretend ...
Cached Medicine News:Health News:Driving Danger -- Black Ice Poses Menace on Frigid NY Roadways, New York Attorney Steven J. Schwartzapfel Says 2Health News:Driving Danger -- Black Ice Poses Menace on Frigid NY Roadways, New York Attorney Steven J. Schwartzapfel Says 3Health News:Driving Danger -- Black Ice Poses Menace on Frigid NY Roadways, New York Attorney Steven J. Schwartzapfel Says 4Health News:Flat Screen TV Stands, TV Mounting Brackets and More: New Site, New Sale, Free Shipping 2Health News:Flat Screen TV Stands, TV Mounting Brackets and More: New Site, New Sale, Free Shipping 3Health News:Preoperative CT useful for younger women with suspected appendicitis 2Health News:Physical Therapist Pleads Guilty in Connection with Detroit Home Health Care Fraud Scheme 2Health News:Physical Therapist Pleads Guilty in Connection with Detroit Home Health Care Fraud Scheme 3Health News:Scott Roeder Trial: Randall Terry, Operation Rescue Founder and Insurrecta Nex Members to Attend Trial in Wichita 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: